Developing a new therapeutic today costs in excess of $2 billion and can take more than a decade before making it to the patient. This cost is largely driven by high rates of attrition of drug candidates, including those advancing to clinical trials. A significant cause of this attrition is unpredicted toxicity. We are addressing the issue of high attrition during drug discovery by developing predictive methods for identifying drugs with a high risk of causing tissue. Specifically, we are building models for drug induced liver injury (DILI), which has been identified as one of the primary reasons for clinical trial failure for compounds across drug classes and disease indications.